UNSPSC 51202806: Umirolimus

This classification denotes an immunosuppressant with the molecular formula C55H87NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U36PGF65JH, chemically known as rapamycin, 42-o-(2-ethoxyethyl)- but more generally known as umirolimus, which bears US NIH Compound Identifier 11158972. European Medicines Agency schedules umirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33179.

UNSPSC 51202806 Umirolimus is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local opportunities tagged under this code show little activity directly aligned with umirolimus procurement. The Illinois Department of Public Health's MMCAP Infuse piggyback award to Chartwell Rx LLC in August 2026 covers Doxycycline Hyclate and Ciprofloxacin Hydrochloride—antibiotic tablets unrelated to umirolimus—while Seminole County, Florida's June 2026 IFB for Naloxone and Safe Drug Deactivation Systems addresses opioid-reversal and drug-disposal products likewise outside the code's stated scope. State and local health departments and counties appear to use pharmaceutical commodity codes for broader warehouse and emergency-supply procurement when leveraging cooperative purchasing agreements and piggyback contracts, rather than for single-ingredient acquisitions. The issuing bodies in recent postings are a state health department and a county government, both sourcing through competitive bidding (IFB) and cooperative vehicles.

Geographic activity centers on Illinois and Florida based on the recent opportunities. The Illinois award involved a 12-month initial term with renewal options and a total contract value of $2,999,999.11, while the Seminole County procurement specified annual quantities (1,900 units of Naloxone, 800 deactivation systems) with quarterly deliveries, an initial two-year term, and one-year renewal option. Both procurements required standard vendor compliance including drug-free workplace certification and E-Verify. No specific set-asides or enterprise preferences were identified in either opportunity. The code's recent posting activity is sparse and the tagged opportunities diverge materially from umirolimus scope, suggesting limited direct procurement volume under this Commodity code in state and local markets.